V

Velocity Clinical Research | Omaha, NE

Research site

(Unclaimed)

Location

3319 N 107th Street, Omaha, Nebraska, United States of America

Site insights

Top conditions

Top treatments

RGT001-075

Orforglipron

MET097

JATENZO®

LY3502970

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 24 total trials

Locations recently updated

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) (ADVANCE)

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccin...

Enrolling

SARS-CoV-2

Biological: mRNA-1273 Variant-containing Formulation

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over...

Active, not recruiting

Chikungunya Virus Infection

Biological: VLA1553